
From OPCRD and CPRD
Patients with ≥ 1 prescriptions for salbutamol reference
n=25,324 unique patients; 196,282 index prescription dates*
Exclusion criteria:
Patients have never received a COPD diagnostic code
(n= 80,400 index prescription dates)
Inclusion criteria:
Patients have received a COPD diagnostic code
Patients received a diagnosis for COPD
(n=115,882 index prescription dates)
Exclusion criteria:
Other chronic respiratory disease code (n=1445 index prescription dates)
Inclusion criteria:
Patients have never received another chronic respiratory disease code, excluding asthma
No other chronic respiratory diagnosis
(n=114,437 index prescription dates)
Exclusion criteria:
Patients aged <40 at date of prescription (n=1583 index prescription dates)
Age ≥40 at IPD
(n=112,854 index prescription dates)
Exclusion criteria:
Patients were not registered at practice for the full 12 months prior to date of prescription or for at least 12 months after date of prescription (n=35,606 index prescription dates)
Inclusion criteria:
Patients registered at practice for at least 12 months prior to date of prescription and for at least 12 months after date of prescription. Date of prescription is within the study period
Valid registration period
(n=77,248 index prescription dates)
Exclusion criteria:
Patients have received a SABA nebulizer in baseline or a SABA nebulizer other than salbutamol reference at index prescription date
(n=1048 patients)
Initiate salbutamol reference
(n=5269 patients)
Continuing salbutamol reference
(n=71,979 index prescription dates)
Exclusion criteria:
Patients have received a SABA nebulizer other than salbutamol reference in baseline or at date of prescription
(n=9464 index prescription dates)
No SABA nebulizer during baseline
(n=4221 patients)
No other SABA nebulizer during baseline
(n=62,515 index prescription dates)
Salbutamol reference
(n=66,736 index prescription dates*)
Initiate (n=4221 patients)
Continuing (n=3717 patients; 62,515 index prescription dates)
*All valid first and continuing prescriptions included as potential matches with the comparator drug